Saltar al contenido principal

ETHNOS_APP

Inicio • Búsqueda • Revistas • Lista 0

Martín Urtasun

Datos Biográficos

ID4197256
NOMBREMartín Urtasun
NOMBRESMartín
APELLIDOUrtasun
FIRMAURTASUN M
AFILIACIONESUniversidad Nacional Arturo Jauretche
ORCID0000-0001-6018-8250
VERIFICADOSí
TOTAL DE OBRAS7
TOTAL DE CITAS0
TOTAL COMO AUTOR7
TOTAL COMO EDITOR0
PRIMER AÑO DE PUBLICACIÓN2017
AÑO MÁS RECIENTE DE PUBLICACIÓN2024
ÍNDICE H0
  • Concordancia entre las listas de medicamentos esenciales y las guías para diabetes en América Latina y el Caribe

    Open Access•Martín Urtasun, Martín Alejandro Urtasun et al.•ARTICLE•Revista Panamericana de Salud…•2024

    Objetivo. Analizar la existencia y actualización de las listas de medicamentos nacionales (LMN) y guías de práctica clínica (GPC) para el tratamiento de la diabetes en América Latina y el Caribe (ALC). Comparar los fármacos incluidos en las listas y guías de cada país, entre sí y con los de la Organización Mundial de la Salud (OMS). Métodos. Estudio de corte transversal. Se identificaron las LMN y GPC para diabetes en los sitios web de la Organiz…

  • Reducción de la cobertura social para los fármacos antiartrósicos sintomáticos de acción lenta

    Open Access•Martín Urtasun, Maria Noble et al.•ARTICLE•Salud Colectiva•2021

    In April 2016, the National Institute of Social Services for Retirees and Pensioners discontinued its policy of 100% coverage for 159 drugs (the "social subsidy"), including symptomatic slow-acting drugs for osteoarthritis (SYSADOAs), due to insufficient evidence of significant clinical benefit. We evaluated the effect of this measure on the use of SYSADOAs as well as non-steroidal anti-inflammatory drugs (NSAIDs), which were unaffected by this p…

  • Consumo de benzodiazepinas y fármacos Z en una organización de la seguridad social nacional argentina

    Open Access•Gustavo H Marin, Julieta Del Mauro et al.•ARTICLE•Salud Colectiva•2021

    Benzodiazepines and "Z-drugs" (BZD/Z) are overprescribed in many countries. This study evaluates their consumption in a social security sector health insurance provider with national coverage in Argentina. With a descriptive and observational approach, outpatient dispensations of BZD/Zs were analyzed for people over 18 years old from April 2020 to March 2021, disaggregated by sex, age, active ingredient, and half-life. An annual prevalence of use…

  • Data transparency for building a stronger healthcare system

    Open Access•Martín Cañás, Gustavo H Marin et al.•ARTICLE•Salud Colectiva•2021

    In order to compile an inventory of national data sources for drug utilization research (DUR) in Argentina and to verify publicly available data sources, we performed a cross-sectional study that sought to identify national and provincial databases of drug use. In July 2020, we searched the websites of government institutions, carried out a systematic query of bibliographic databases for “drug utilization research” conducted in Argentina, and con…

  • Regulatory reliance to approve new medicinal products in Latin American and Caribbean countries

    Open Access•Carlos E Durán, Martín Cañás et al.•ARTICLE•Revista Panamericana de Salud…•2021

    Regulatory reliance has become a common practice in the LAC region. Thirteen out of 20 regulators directly recognize or abbreviate the marketing authorization process in case of earlier approval by a regulator from another jurisdiction. The regulators most relied upon are the European Medicines Agency, United States Food and Drug Administration, and Health Canada

  • Valor terapéutico y precio de los nuevos fármacos comercializados en Argentina

    Open Access•Martín Cañás, H Buschiazzo et al.•ARTICLE•Salud Colectiva•2019

    In Argentina, new drugs can be authorized by presenting the drug's certificate of approval in at least one of 15 countries considered to have rigorous health surveillance, without needing to carry out a local evaluation of the efficacy, safety or added therapeutic value of the new product. In this article, we evaluate the new drugs commercialized in Argentina in 2016 using different approaches: their approval by other regulatory agencies, the dem…

  • Devolviendo la mirada. Interrogantes y claves de lectura para la investigación de la videovigilancia

    Open Access•Vanesa Lio, Martín Urtasun•ARTICLE•Delito y sociedad. Revista de…•2017

    Americanae nace como un proyecto conjunto que surge dentro de la Red Europea de Información y Documentación sobre América Latina (REDIAL), y que ha afrontado la Biblioteca de la Agencia Española de Cooperación Internacional para el Desarrollo (AECID). Esta nueva biblioteca virtual hace más accesibles los libros digitales de tema americanista a los investigadores y usuarios interesados de cualquier parte del mundo

Sin obras prominentes en esta página.

  • Devolviendo la mirada. Interrogantes y claves de lectura para la investigación de la videovigilancia

    Open Access•Vanesa Lio, Martín Urtasun•ARTICLE•Delito y sociedad. Revista de…•2017

    Americanae nace como un proyecto conjunto que surge dentro de la Red Europea de Información y Documentación sobre América Latina (REDIAL), y que ha afrontado la Biblioteca de la Agencia Española de Cooperación Internacional para el Desarrollo (AECID). Esta nueva biblioteca virtual hace más accesibles los libros digitales de tema americanista a los investigadores y usuarios interesados de cualquier parte del mundo

  • Valor terapéutico y precio de los nuevos fármacos comercializados en Argentina

    Open Access•Martín Cañás, H Buschiazzo et al.•ARTICLE•Salud Colectiva•2019

    In Argentina, new drugs can be authorized by presenting the drug's certificate of approval in at least one of 15 countries considered to have rigorous health surveillance, without needing to carry out a local evaluation of the efficacy, safety or added therapeutic value of the new product. In this article, we evaluate the new drugs commercialized in Argentina in 2016 using different approaches: their approval by other regulatory agencies, the dem…

  • Reducción de la cobertura social para los fármacos antiartrósicos sintomáticos de acción lenta

    Open Access•Martín Urtasun, Maria Noble et al.•ARTICLE•Salud Colectiva•2021

    In April 2016, the National Institute of Social Services for Retirees and Pensioners discontinued its policy of 100% coverage for 159 drugs (the "social subsidy"), including symptomatic slow-acting drugs for osteoarthritis (SYSADOAs), due to insufficient evidence of significant clinical benefit. We evaluated the effect of this measure on the use of SYSADOAs as well as non-steroidal anti-inflammatory drugs (NSAIDs), which were unaffected by this p…

  • Consumo de benzodiazepinas y fármacos Z en una organización de la seguridad social nacional argentina

    Open Access•Gustavo H Marin, Julieta Del Mauro et al.•ARTICLE•Salud Colectiva•2021

    Benzodiazepines and "Z-drugs" (BZD/Z) are overprescribed in many countries. This study evaluates their consumption in a social security sector health insurance provider with national coverage in Argentina. With a descriptive and observational approach, outpatient dispensations of BZD/Zs were analyzed for people over 18 years old from April 2020 to March 2021, disaggregated by sex, age, active ingredient, and half-life. An annual prevalence of use…

  • Data transparency for building a stronger healthcare system

    Open Access•Martín Cañás, Gustavo H Marin et al.•ARTICLE•Salud Colectiva•2021

    In order to compile an inventory of national data sources for drug utilization research (DUR) in Argentina and to verify publicly available data sources, we performed a cross-sectional study that sought to identify national and provincial databases of drug use. In July 2020, we searched the websites of government institutions, carried out a systematic query of bibliographic databases for “drug utilization research” conducted in Argentina, and con…

  • Regulatory reliance to approve new medicinal products in Latin American and Caribbean countries

    Open Access•Carlos E Durán, Martín Cañás et al.•ARTICLE•Revista Panamericana de Salud…•2021

    Regulatory reliance has become a common practice in the LAC region. Thirteen out of 20 regulators directly recognize or abbreviate the marketing authorization process in case of earlier approval by a regulator from another jurisdiction. The regulators most relied upon are the European Medicines Agency, United States Food and Drug Administration, and Health Canada

  • Concordancia entre las listas de medicamentos esenciales y las guías para diabetes en América Latina y el Caribe

    Open Access•Martín Urtasun, Martín Alejandro Urtasun et al.•ARTICLE•Revista Panamericana de Salud…•2024

    Objetivo. Analizar la existencia y actualización de las listas de medicamentos nacionales (LMN) y guías de práctica clínica (GPC) para el tratamiento de la diabetes en América Latina y el Caribe (ALC). Comparar los fármacos incluidos en las listas y guías de cada país, entre sí y con los de la Organización Mundial de la Salud (OMS). Métodos. Estudio de corte transversal. Se identificaron las LMN y GPC para diabetes en los sitios web de la Organiz…

Political science (6 obras) · Humanities (4 obras) · Medicine (4 obras) · Health Systems, Economic Evaluations, Quality of Life (3 obras) · Pharmaceutical Economics and Policy (3 obras) · Art (2 obras) · Business (2 obras) · Healthcare Systems and Reforms (2 obras) · Internal Medicine (2 obras) · Latin Americans (2 obras)

Ethnos_APP • Proyecto Open Source • Licencia MIT • Frontend v2.0.0 • Privacidad y Cookies • Documentación de la API: api.ethnos.app/docs • Código de la API: GitHub • DOI: 10.5281/zenodo.17049435 • Código del Frontend: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae